Showing 676 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

New & experimental HIV treatments

Scripps Research Institute-Designed Drug Candidate Significantly Reduces HIV Reactivation Rate

Editor's pick
Scripps Research Institute
11 July 2015
PrEP

Could a Subdermal Implant Mean the End of HIV?

Editor's pick
Edge San Francisco
6 July 2015
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Single Tablet Regimen for HIV Containing Rilpivirine, Emtricitabine and Tenofovir Alafenamide

Editor's pick
Gilead press release
2 July 2015
New & experimental HIV treatments

European Medicines Agency Validates Gilead’s Marketing Application for Fixed-Dose Combination of Emtricitabine and Tenofovir Alafenamide (F/TAF) for HIV Treatment

Editor's pick
Gilead
2 June 2015
Access to healthcare

ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV

Editor's pick
ViiV Healthcare
26 May 2015
New & experimental HIV treatments

EMA Panel Recommends Evotaz for Adults With HIV-1

Editor's pick
Medscape
26 May 2015
New & experimental HIV treatments

New subdermal implant delivers potent antiretroviral drugs

Editor's pick
Science Daily
29 April 2015
New & experimental HIV treatments

Six questions about HIV/AIDS that deserve more attention

Editor's pick
Eurekalert Inf Dis
15 April 2015
New & experimental HIV treatments

Mechanism of action of ABIVAX’s First-in-class anti-HIV drug published today in peer-reviewed journal Retrovirology

Editor's pick
ABIVAX press release
14 April 2015
The search for a cure

Editing HIV out of our genome with CRISPR

Editor's pick
University of Massacusetts Medical Schoool press release
13 April 2015
New & experimental HIV treatments

Broadly Neutralizing Antibody Suppresses HIV in Clinical Trial

Editor's pick
TAG
10 April 2015
New & experimental HIV treatments

In first human study, new antibody therapy shows promise in suppressing HIV infection

Editor's pick
Rockefeller University press release
9 April 2015
New & experimental HIV treatments

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment

Editor's pick
Gilead press release
8 April 2015
New & experimental HIV treatments

New lead against HIV could finally hobble the virus’s edge

Editor's pick
American Chemical Society
24 March 2015
New & experimental HIV treatments

HIV treatment: New inexpensive agents can block virus ability to replicate and develop resistance

Editor's pick
International Business Times
20 March 2015
The search for a cure

Beware Of Sangamo: 20-Year History Of Failures, Misadventures In HIV, And Flawed Approach In B-Thalassemia

Editor's pick
Seeking Alpha
10 March 2015
New & experimental HIV treatments

48-week analysis of investigational HIV-1 attachment inhibitor paves way for Phase III trial initiation

Editor's pick
Bristol Myers Squibb press release
26 February 2015
The search for an HIV prevention vaccine

Experimental AIDS Drug Stirs Talk Of Vaccine 'Alternative'

Editor's pick
Huffington Post
19 February 2015
New & experimental HIV treatments

CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy

Editor's pick
CytoDyn press release
5 February 2015
Neurological & cognitive problems

Researchers identify key mechanisms underlying HIV-associated cognitive disorders

Editor's pick
Medical Xpress
4 February 2015
New & experimental HIV treatments

Treatment of the First HIV Positive Patient in ABIVAX's Phase IIa Clinical Trial With ABX464

Editor's pick
ABIVAX press release
2 February 2015
New & experimental HIV treatments

PREZCOBIX™ (darunavir/cobicistat) approved in the U.S. for the treatment of adults living with HIV-1

Editor's pick
Janssen press release
30 January 2015
New & experimental HIV treatments

U.S. Food and Drug Administration approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the treatment of HIV-1 infection in adults

Editor's pick
Bristol-Myers Squibb press release
30 January 2015
Pharmaceutical industry

Merck (MRK) Receives Positive CHMP Opinion for Dutrebis as HIV 1 Treatment

Editor's pick
Street Insider
26 January 2015